India, Aug. 10 -- Silo Pharma, Inc. (SILO), a developmental-stage biopharmaceutical and an AI agent platform, on Monday announced that the European Patent Office (EPO) has granted a patent covering its lead candidate, SPC-15.
SPC-15 is an intranasal, nose-to-brain therapy being developed for post-traumatic stress disorder (PTSD) and stress-induced affective disorders.
The granted European Patent No. EP3952852 titled "Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress" covers the methods of preventing stress-induced fear, depressive-like behaviour and associated affective disorders. The drug works by administering selected serotonin 4 (5-HT4) receptor agonists before exposure to a stressor, including potentially extreme ...